0001209191-21-061556.txt : 20211025 0001209191-21-061556.hdr.sgml : 20211025 20211025183049 ACCESSION NUMBER: 0001209191-21-061556 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20211022 FILED AS OF DATE: 20211025 DATE AS OF CHANGE: 20211025 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Duncan Jason CENTRAL INDEX KEY: 0001741553 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33451 FILM NUMBER: 211345270 MAIL ADDRESS: STREET 1: C/O ALBIREO PHARMA, INC. STREET 2: 10 POST OFFICE SQUARE, SUITE 502 SOUTH CITY: BOSTON STATE: MA ZIP: 02109 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ALBIREO PHARMA, INC. CENTRAL INDEX KEY: 0001322505 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 10 POST OFFICE SQUARE STREET 2: SUITE 502 SOUTH CITY: BOSTON STATE: MA ZIP: 02109 BUSINESS PHONE: 857-415-4774 MAIL ADDRESS: STREET 1: 10 POST OFFICE SQUARE STREET 2: SUITE 502 SOUTH CITY: BOSTON STATE: MA ZIP: 02109 FORMER COMPANY: FORMER CONFORMED NAME: Biodel Inc DATE OF NAME CHANGE: 20050331 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-10-22 0 0001322505 ALBIREO PHARMA, INC. ALBO 0001741553 Duncan Jason C/O ALBIREO PHARMA, INC. 10 POST OFFICE SQUARE, SUITE 1000 BOSTON MA 02109 0 1 0 0 Chief Legal Officer and GC Common Stock 2021-10-22 4 S 0 95 28.8508 D 7572 D Common Stock 2021-10-25 4 S 0 217 29.21 D 7355 D Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.8350 to $28.8974, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. Represents 509 shares of common stock and 7,063 restricted stock units. Shares sold pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 1, 2021. Represents 292 shares of common stock and 7,063 restricted stock units. /s/ Jason Duncan 2021-10-25